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See Focus, pages 905–906Background & Aims: One-year survival in cirrhosis ranges from 1
to 57% depending on the clinical stage. Accurate sub-classiﬁcation
has important prognostic implications but there is no stage
beyond cirrhosis using current qualitative histological systems.
We compared the performance of all histological semi-quantita-
tive and quantitative methods speciﬁcally developed for sub-clas-
sifying cirrhosis that have been described to date, with collagen
proportionate area (CPA), to evaluate how well they distinguish
patients with andwithout hepatic clinical decompensation at pre-
sentation, and in predicting future decompensating events.
Methods:We included consecutive patients with a histological
diagnosis of cirrhosis that had a suitable liver biopsy between
2003 and 2007. We used semi-quantitative histological scoring
systems proposed by Laennec, Kumar, and Nagula. We also mea-
sured quantitatively nodule size, septal width and ﬁbrous tissue
expressed in CPA.
Results: Sixty-nine patients, mean age 52.3 ± 11 years, mean
MELD 11.8 ± 5.8, median follow-up 56 months. Main aetiologies
were alcohol (38%) and hepatitis C (27.5%). Twenty-four patients
(34.8%) had had a previous episode of clinical decompensation.
Amongst the 45 patients who were compensated, 11 (24%)
decompensated on follow-up. In Cox regression, amongst all his-
tological parameters, CPA was the only variable independently
associated with clinical decompensation up to the time of biopsy,
with an odds ratio that ranged from 1.245 to 1.292. Furthermore,
only CPA was signiﬁcantly associated with future decompensa-
tion (OR: 1.117, 95% CI 1.020–1.223; p = 0.017).
Conclusions: Cirrhosis can be accurately sub-classiﬁed using
quantiﬁcationof ﬁbrosiswithCPA, and furthermoreCPA is the only
independent predictor of clinical decompensation amongst all
other histological sub-classiﬁcation systems described to date.Journal of Hepatology 20
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Introduction
Cirrhosis is the common endpoint of various aetiologies of liver
injury and represents the severest histological stage. For decades
cirrhosis has been considered to signal an invariably dismal progno-
sis andequatedwith end stage liver disease. However, it is becoming
increasingly apparent that cirrhosis is not a single disease stage, and
that prognosis is highly variable, with one-year mortality ranging
from 1 to 57% [1]. Therefore, compensated and decompensated cir-
rhosis has been further sub-classiﬁed into several clinical prognostic
stages, with distinct differences in mortality between them [2–4].
In traditional qualitative histological systems, cirrhosis [5] is the
last histological stage and therefore these cannot be used to address
the increasing needof further prognostication.More recently, histo-
logical systems of sub-classifying cirrhosis have been used, mainly
based on semi-quantitative evaluation of nodular size and septal
width. These includeproposalsbyLaennecbasedon theoriginal his-
tological description of cirrhosis [6–8], by Nagula [9] and Kumar
[10]; all have used hepatic vein pressure gradient (HVPG) as a surro-
gate endpoint in parallel with Laennec’s system. A purely quantita-
tive assessment of nodules and septawas recently described, which
correlatedwellwithHVPG [11]. Our groupdeveloped a quantitative
method of measuring ﬁbrous tissue, using digital image analysis of
the proportion of collagen in liver tissue, namely collagen propor-
tionate area (CPA) [12]. Thismethodhas beenvalidatedbothagainst
HVPG and clinical outcomes [12–15].
In the present study,we compared the performance of all histo-
logical semi-quantitative and quantitative methods speciﬁcally
developed and described to date, for sub-classifying cirrhosis with
CPA, to evaluate howwell they could distinguish patientswith and
without hepatic clinical decompensation at presentation, and in
predicting future decompensating events.
Patients and methods
Patient selection
We included consecutive patients with a histological diagnosis of cirrhosis, biop-
sied at the Royal Free Hospital between 2003 and 2007. We included liver
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Table 1. Baseline patient characteristics.
Age, yr 52.3 ± 11
Sex, males (%) 42 (60.9)
Aetiology of chronic liver disease (%)
ALD
HCV
HBV
NASH
Autoimmune hepatitis
Other
26 (37.7)
19 (27.5)
6 (8.7)
6 (8.7)
4 (5.8)
8 (11.5)
MELD 11.8 ± 5.8
Child-Pugh score 6.7 ± 2.5
Child-Pugh class (%)
A
B
C
44 (63.8)
13 (18.8)
12 (17.4)
Decompensated at biopsy (%) 24 (34.8)
Decompensate at follow-up (%) 11 (24)
Follow-up, months 54 ± 39 (median = 56)
Quantitative values are expressed as mean ± standard deviation.
ALD, alcoholic liver disease; NASH, non-alcoholic steatohepatitis; MELD, model
for end stage liver disease.
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biopsies P10 mm in length. We collected baseline characteristics, including
demographic and laboratory parameters and documented episodes of decompen-
sation prior or at the time of the liver biopsy. Patients’ follow-up data were col-
lected until their ﬁrst episode of clinical decompensation or until December 2012.
Decompensation was deﬁned as any episode of variceal bleeding, clinically
detectable ascites, encephalopathy or non-obstructive jaundice. We censored
patients at the time of a liver transplant, development of HCC, date of sustained
virological response (SVR) if treated for HCV, date of undetectable viral load if
treated for HBV, and at 6 months of complete abstinence in cases of alcohol-
related cirrhosis. Patients with cirrhosis after liver transplantation were excluded.
Liver biopsy samples
Liver biopsies were performed either transjugularly with a 19G TruCut needle
[14] or percutaneously with a 16G Menghini needle.
Liver biopsy samples were formalin-ﬁxed, parafﬁn-embedded and routinely
stained with hematoxylin and eosin (H&E), DPAS (PAS stain with diastase diges-
tion), orcein, Victoria Blue and Perl’s. Another section of tissue was stained with
picro-Sirius red for collagen quantiﬁcation and determination of CPA by digital
image analysis (DIA). Two pathologists (TVL and SB), blinded to clinical data,
independently evaluated all biopsies and performed the semi-quantitative analy-
ses. Where there was disagreement in the scoring of any sample, the sections
were re-assessed by both pathologists together and a consensus reached. A single
operator (SB) performed the quantitative nodule and septal width measurements.
CPA measurements were performed by AH.
Histological sub-classiﬁcation
The Laennec [6,7], Kumar [10], Nagula [9], and Sethasine [11] sub-classiﬁcation
were performed as previously described (see Supplementary Materials and meth-
ods for details).
Collagen proportionate area using digital image analysis (DIA)
This method is described in detail elsewhere [12,16]. In summary, the Sirius Red
stained biopsy sections were used for DIA. The equipment used was a digital cam-
era (Canon Powershot A640 attached to a close-up copy-stand with backlighting)
connected to a compatible personal computer. Calibration of the camera was:
154  154 pixels = 23,716 = 1 mm2. After whole section digital image capture,
CPA was measured with Zeiss KS300 image analysis software. A RGB (Red, Green,
Blue) threshold was then used to detect areas of stained collagen and the collagen
mask was calculated as an area in pixels. A ratio (CPA) is expressed as a percent-
age. Tissue within 5 mm of the capsule and large blood vessels were avoided. The
CPA measurement includes a manual editing step to eliminate image artifacts,
and operator dependent thresholding to determine the stained area of the
section.
Statistical analysis
All data were analysed using the statistical package SPSS (version 21.0, IBM). Sta-
tistical analysis was performed using t test, ANOVA, Mann-Whitney or Kruskal-
Wallis tests for comparisons of continuous variables between or among groups,
corrected Chi squared method or two-tailed Fisher’s exact test for comparisons
of qualitative data and Spearman’s co-efﬁcient for correlations of quantitative
data, when appropriate. Multivariate and survival analyses were performed using
logistic regression and Cox regression models respectively. Only variables with p
values 60.10 at univariate analysis were entered in the multivariate analysis
models. A two-tailed p value <0.05 was considered statistically signiﬁcant.Results
Patient ﬂow
A total of 159 patients had histological cirrhosis diagnosed [5]
between 2003 and 2007. We excluded the following: 16 because
the histological diagnosis was of incomplete cirrhosis, 41 because
biopsy samples were too short (length <10 mm) and 22 because
the biopsies were too fragmented (>4–5 fragments). ExclusionJournal of Hepatology 201was not because biopsies were suboptimal for the diagnosis of
cirrhosis. The too short or fragmented samples were excluded,
as a minimummeasurement of 5 nodules required by Sethasine’s
method was not feasible, while with fragmentation ﬁbrous septa
are often missed, thus measurement is not possible. CPA can be
reliably performed in fragmented samples of adequate length,
but not in too short samples [16]. A further 11 post transplant
cases were excluded, leaving 69 patients as the study population.
Patient characteristics
Mean age was 52.3 ± 11 years. Alcohol was the main aetiology
(38%) followed by hepatitis C (27.5%). Mean MELD score was
11.8 ± 5.8 (median 10); the distribution across Child classes
was: A (63.8%), B (18.8%), and C (17.4%). At the time of the biopsy,
24 patients (34.8%) had had a previous episode of clinical decom-
pensation; of the 45 patients who were compensated, 11 (24%)
had at least one episode of clinical decompensation during a
median follow up of 56 months. All patient characteristics are
summarized in Table 1.
Histological characteristics
Forty-two patients had a transjugular liver biopsy (TJLB) and the
rest a percutaneous one (PLB). The mean biopsy length was
21.6 ± 8.2 mm (range 10–46.3), with TJLB samples being signiﬁ-
cantly longer (TJLB vs. PLB 23.9 ± 8.9 vs. 18 ± 5.4 mm, p = 0.003).
The median TJLB width was 0.65 mm (range 0.5–0.7), whereas
the median PLB width was 1.18 mm (range 1.0–1.5). The median
number of nodules/biopsy was 15. The distribution according to
Laennec classiﬁcation was 5.8%, 44.9%, and 49.3% in classes 4a,
4b, and 4c respectively. The median nodule size across different
Laennec classes was 1643 (range 954–2993) lm for 4a, 1068
(range 536–2357) lm for 4b and median 793 (range 344–
1933) lm for 4c. Most patients were categorized as Kumar class4 vol. 60 j 948–954 949
Table 2. Patients’ histological characteristics.
Transjugular biopsies (%) 42 (60.9)
Biopsy length, mm 21.6 ± 8.2
Number of nodules/biopsy 15 (6-49)
Nodules/mm of biopsy 0.86 (0.35-2.07)
Nodule size, μm 1070 (343-2993)
Septal width, μm 213 (54-2137)
CPA
Laennec sub-classification (%)
Kumar sub-classification (%)
23 ± 12.4
4a
4b
4c
4 (5.8)
31 (44.9)
34 (49.3)
A (score 1-3)
B (score 4-6)
6 (8.7)
63 (91.3)
Nodule size (%)
Small
Mixed
Large
2 (2.9)
66 (95.6)
1 (1.5)
Septal thickness  (%)
Thin
Medium
Thick
5 (7.2)
36 (52.2)
28 (40.6) 
Quantitative values are expressed as mean ± standard deviation or median
(range).
CPA, collagen proportionate area.
Research ArticleB (63, 91%). Only 2 patients (2.9%) had small cirrhotic nodules, 66
(95.7%) had mixed sizes and 1 (1.4%) had large nodules according
to the Nagula classiﬁcation. Septa were thin in 5 patients (7.2%),
medium in 36 (52.2%) and thick in 28 (40.6%) according to the
same classiﬁcation. Mean CPA was 23 ± 12.4. All the above is
summarized in Table 2.
CPA correlation with other histological parameters
CPA increased signiﬁcantly across the Laennec scoring system,
with mean values in stages 4a vs. 4b vs. 4c of 9.1 ± 5.2,
15.8 ± 6.3, and 31.3 ± 11.5 respectively (p <0.001). This difference
was also present in the Kumar classiﬁcation, with CPA in class A
vs. B being 8.7 ± 4.7 vs. 24.4 ± 12.1 (p = 0.003). CPA also increased
as septal thickness increased, with values of 9.2 ± 4.5, 17.7 ± 7.8
and 32.4 ± 11.8 in thin, medium and thick septa respectively
(p <0.001). The difference was less pronounced as nodule size
increased, probably due to the small number of patients with
small nodules (mean values in small and mixed were 36.4 ± 7.1,
22.9 ± 12.2 respectively, p = 0.069, only one patient with large
nodules). The above is shown in Fig. 1.
CPA signiﬁcantly and positively correlated with septal width
(r = 0.622, p <0.001) and negatively with size of nodules
(r = 0.620, p <0.001), while there was no correlation with num-
ber of nodules or nodules/mm of tissue (p = n.s.).
Time required for histological analysis
Histological sub-classiﬁcation using semi-quantitative methodol-
ogy required an average of 5 min/sample. CPA analysis, including
the manual editing of removing the structural collagen from
the measurement area, required an average of 10 min/sample.950 Journal of Hepatology 201Quantitative measurement of septal thickness and nodule size
required 20–30 min/sample depending on the number of nod-
ules, which is compatible with the timing in the original publica-
tion (Garcia-Tsao, personal communication). All the above
represent the average time spent per operator after the initial
training period.
Predictors of decompensation at the time of biopsy
All histological parameters were tested as potential predictors of
clinical decompensation up to the time of biopsy. Laennec stage
was associated with decompensation (decompensation in 4a vs.
4b vs. 4c was 0% vs. 12.9% vs. 59%, p <0.001), while Kumar stage
was only marginally associated (decompensation in A vs. B was
0/6 vs. 24/63, p = 0.085). Patients with thick or medium septa
were more likely to be decompensated, than patients with thin
septa (61% vs. 19% vs. 0% respectively, p = 0.001), while there
was no signiﬁcant association of decompensation with the pre-
dominant size of nodules (decompensation in small vs. mixed
vs. large was 100% (2/2) vs. 33% (22/66) vs. 0% (0/1), p = n.s.).
Quantitative septal width (p = 0.020), nodule size (p <0.001),
and CPA (16.9 ± 7.5 vs. 34.5 ± 11.6, p <0.001) were signiﬁcantly
associated with decompensation. Finally, patients with decom-
pensation had signiﬁcantly higher MELD score than patients
without (17.4 ± 6.1 vs. 8.9 ± 2.6, p <0.001).
In the multivariate analysis, we entered CPA separately with
each proposed sub-classiﬁcation systems of cirrhosis of Laennec
[6,7] and Kumar [10], with septal thickness and nodule size (Nag-
ula classiﬁcation) [9], and with quantitative septal width and
nodule size (Sethasine et al.) [11], and therefore evaluated four
different models. In all cases, CPA was the only variable indepen-
dently associated with clinical decompensation up to the time of
biopsy, with an odds ratio that ranged from 1.245 to 1.292
(Table 3). We ﬁnally entered both CPA and MELD in the multivar-
iate model, and both emerged as independent predictors of the
presence of baseline decompensation (Table 3).
The AUROC of CPA alone to predict baseline clinical decom-
pensation was 0.909, and a cut-off of 25.5 had a sensitivity of
0.875 and a speciﬁcity of 0.889. Comparative AUROCs are shown
in Fig. 2.
Future decompensating events
Mean follow-up was 59 ± 38 (median 65) months, during which,
11/45 (24%) patients compensated at baseline developed a
decompensating event (3 were transplanted and 2 died). Most
had ascites as the ﬁrst decompensation event (8/11, 73%). In
Cox regression analysis, the Laennec, Kumar and Nagula semi-
quantitative sub-classiﬁcation parameters and also the quantita-
tively measured septal thickness and nodular size were not asso-
ciated with future decompensation. The previously published
cut-off of 169.01 lm for septal width [17] was not associated
with future decompensation. Amongst histological parameters,
only CPA was signiﬁcantly associated with future decompensa-
tion (OR: 1.117, 95% CI 1.020–1.223; p = 0.017).Discussion
In the present study, we showed that of all the histological
methods used to date, to sub-classify cirrhosis [6–11], CPA4 vol. 60 j 948–954
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Fig. 1. Distribution of CPA values across semi-quantitative stages of cirrhosis.
(A) Laennec classiﬁcation. (B) Nodule dimension according to Nagula. (C) Septal
thickness according to Nagula. (D) Kumar classiﬁcation.
Table 3. Multivariate models of predictors of clinical decompensation at the
time of baseline biopsy in 69 patients with cirrhosis.
Variable OR 95% CI p value
Model 1
CPA 1.249 1.101-1.417 0.001
Laennec n.s.
Model 2
CPA 1.245 1.119-1.385 <0.001
Kumar n.s.
Model 3
CPA 1.249 1.101-1.416 0.001
Septal thickness n.s.
Nodular size n.s.
Model 4
CPA 1.292 1.127-1.482 <0.001
Septal thickness n.s.
Nodular size n.s.
Model 5
CPA 1.196 1.054-1.357 0.005
MELD 1.383 1.111-1.720 0.004
Model 3 includes the semi-quantitative parameters proposed by Nagula et al.
Model 4 includes the quantitative parameters proposed by Sethasine et al.
OR, odds ratio; CI, conﬁdence interval; CPA, collagen proportionate area; MELD,
model for end stage liver disease; n.s., not signiﬁcant.
Fig. 2. Comparative areas under the ROC (AUROCs) of semi-quantitative and
quantitative sub-classiﬁcation methods of cirrhosis to predict future clinical
decompensation in patients with compensated cirrhosis at baseline. AUROCs
are: CPA = 0.909; 1-nodule size (Sethasine) = 0.79; Laennec = 0.769; septal thick-
ness (Sethasine) = 0.748; septal width = 0.671; Kumar = 0.567; node dimension
(Nagula) = 0.44. (This ﬁgure appears in colour on the web.)
JOURNAL OF HEPATOLOGYindependently and most strongly predicts both decompensation
at baseline and most importantly future clinical decompensating
events. Whereas other published studies explored one method at
a time, we were able to compare all published methods in the
same patient cohort using the hard endpoint of clinical outcomes.
Sub-classiﬁcation of cirrhosis is becoming an increasing clini-
cal need, as new approaches and strategies to prevent and delay
patients from progressing to decompensation are emerging
[18,19]. MELD and UKELD scores are used for deciding on when
to transplant patients, however they are applicable only very late
in the disease process and cannot be used for prognosis in the
early stages of cirrhosis. Non-invasive tests have recently been
shown to predict clinical decompensation in patients with
advanced ﬁbrosis or early cirrhosis [20]. Ideally, the predictive
ability of these tools should be compared to semi-quantitative
or quantitative histological methods of sub-classiﬁcation of cir-
rhosis [21].
Histological semi-quantitative methods of sub-classiﬁcation
represent a more detailed way of further sub-classifying the pre-
viously termed micro- and macronodular cirrhosis. Amongst the
semi-quantitative methods described, the Laennec classiﬁcation,
with three sub-categories, has been studied in the greatest num-
ber of patients with various aetiologies of liver disease, and cor-
related both with portal hypertension as assessed by HVPG [6,8]
and liver related clinical outcomes [7]. The classiﬁcation pro-
posed by Nagula independently assessed septal width and nodule
size, which was predictive of clinically signiﬁcant portal hyper-
tension in 43 patients with various aetiologies of cirrhosis [9].
Kumar et al. used a variant of the Nagula classiﬁcation, with
two sub-categories that correlated with clinically signiﬁcant por-
tal hypertension in 47 patients with HBV cirrhosis [10].Journal of Hepatology 201Although semi-quantitative sub-classiﬁcation is fairly simple
and quick, and does not need specialized equipment, it is still a
crude tool for sub-classifying cirrhosis and offers no more than
two or three further stages. Indeed, there is signiﬁcant overlap
in HVPG values among patients with Laennec stages 4a and 4b
[6], and amongst those with thin and medium septa or large
and mixed nodules [9,10]. Furthermore the Laennec sub-classiﬁ-
cation system and similar semi-quantitative histological methods
have an evaluation bias represented by the width of the biopsy,
as all are based on a subjective evaluation of the nodule size4 vol. 60 j 948–954 951
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m
Fig. 3. Evaluation of septal thickness in relation to the liver biopsy width (Sirius Red, X5). A ﬁbrous septum >0.65 mm [transjugular liver biopsy median (TJLB) width],
but <1.18 mm [percutaneous liver biopsy (PLB) median width] could be considered as a ‘‘very broad septum’’ according to the Laennec system if the biopsy was a TJLB or
could be downgraded to ‘‘broad septum’’ if the biopsy was a PLB, changing the Laennec’s stage 4c to 4b in cases where less than half of biopsy length was composed of
minute nodules. (This ﬁgure appears in colour on the web.)
Research Articleand septal thickness in relation to the biopsy width, without a
precise and rigorous deﬁnition of nodule size and septal
thickness.
Kim [6], Kumar [10], and Rastogi [8] described that only liver
biopsies with a width of >1.2 mm were included in their studies.
The cut-off of biopsy width >1.2 mm is arbitrary and if this value
is adopted in routine practice it would exclude many PLBs and all
TJLBs from the assessment. Percutaneous liver biopsy with a 15G
Menghini needle has an average width of 0.75 mm in ﬁxed tissue
as Menghini described in his original paper [22]. Transjugular
liver biopsies using a 19G Tru-cut needle have a histological med-
ian width of 0.6 mm (range 0.4–0.8) [16,22]. In the current study
the median TJLB width was 0.65 mm (range 0.5–0.7); whereas
the median PLB width was 1.18 mm (range 1.0–1.5). Nowadays
patients with more advanced cirrhosis are more likely to have a
transjugular rather than a percutaneous biopsy.
There were 8 TJLBs (12%) classiﬁed as Laennec 4c because
there was a ‘‘very broad septum’’ (deﬁned as the region of extinc-
tion wider than 1 biopsy width). As the median width of the PLBs
was greater than TLJBs (median 0.65 vs. 1.18 mm), if these 8 cases
had been PLBs, they could have been subcategorised as Laennec
4b (Fig. 3). Similarly as the size of a nodule was deﬁned in rela-
tion to biopsy width, a nodule measured between 0.65 mm and
1.18 mm, could have been deﬁned as ‘‘small nodule’’ in a PLB
and ‘‘large nodule’’ in a TJLB.
More recently, a purely quantitative method of sub-classify-
ing cirrhosis has been described, that takes into account ﬁbro-
sis area, septal width and nodule size [11]. The authors
themselves acknowledged that their method is cumbersome
and less accurate than the ‘‘bird’s eye’’ view for the assessment952 Journal of Hepatology 201of nodules and septa [11]. We were able to reproduce this
method for septal width and nodule size assessment, conﬁrm-
ing that the method is not time-effective for routine practice.
Furthermore, we agree with the authors that the quantiﬁcation
of median nodule size and median septal width can average
different sizes and may over-represent a non-predominant type
of nodule. In our study, although >3 mm nodules were mea-
sured, this ﬁnding was not apparent in the presentation of
the ﬁnal data (Table 2), because the median nodule size value
‘‘discounted’’ the outlying values. A further problem is that
ﬁbrosis area is still not validated against clinical outcomes,
has been only used in a limited number of patients and has
provided contradictory results even when analyzing the same
patient cohort [11,17]. A recent publication using ﬁbrosis area
was also inconclusive, as it did not evaluate its predictive value
in multivariate analysis [8].
We used CPA instead of ﬁbrosis area for quantifying ﬁbrosis.
CPA compared to ﬁbrosis area has an additional manual step of
editing structural collagen and therefore offers increased accu-
racy in calculating the parenchymal ﬁbrous tissue collagen [12].
Our analysis revealed that CPA increased proportionately across
all stages of cirrhosis using the semi-quantitative sub-classiﬁca-
tion systems described, and more importantly, that it was the
only independent histological predictor of clinical decompensa-
tion. This was not unexpected, as thicker cirrhotic septa contain
more collagen. Moreover, it added to MELD in the diagnosis of
decompensation up to the time of biopsy and thus provided addi-
tional prognostic information. Finally, despite the limited number
of patients who were compensated at baseline and the small
number of decompensating events at follow up, CPA was the only4 vol. 60 j 948–954
BA
Fig. 4. Liver biopsies. Patients without (A) and with (B) clinical decompensation.
In both, there were mixed, variably sized nodules and variable septal width with
at least one very broad septum and predominant medium to thick type of septae.
Although the two biopsies could look different, both biopsies had same Laennec
stage cirrhosis (4c), same Kumar stage B and same Nagula’s mixed nodules.
Nagula’s septum was medium in (A) and thick in (B). In (A), the median nodule
size according to Sethasine’s method was 270.12 lm and median septal width
was 120.05 lm; whilst in (B), the median nodule size was 250.30 lm and median
septal width was 180.60 lm, despite the presence of large nodules in (A) (largest
nodule in (A) was 3020.30 lm and in (B) was 940.70 lm) and thick ﬁbrous septa
in (B) (widest septum in (A) was 210.25 lm and in (B) was 960.80 lm), as the
median value discounted the outlying ﬁgures. Only collagen proportionate area
(CPA) was able to clearly demonstrate the difference between the two biopsies:
21.6% in A and 46% in B. (This ﬁgure appears in colour on the web.)
JOURNAL OF HEPATOLOGYhistological variable signiﬁcantly associated with the develop-
ment of such events. Therefore, our results provide a proof of con-
cept that measurement of CPA is currently the best method for
accurate sub-classiﬁcation of cirrhosis. This is also illustrated in
Fig. 4.
Currently, CPA is a well-validated method of ﬁbrosis quantiﬁ-
cation that has been assessed in cirrhotic and non-cirrhotic
cohorts and in pre- and post-transplant populations and, more
importantly, has been validated against liver-related clinical out-
comes [12–15,23]. Additional work has shown that ﬁbrosis distri-
bution is not statistically different across liver lobes in cirrhosis
[24] and that the sample required to assess CPA is not larger than
that of the standard liver biopsy [16]. It is a fairly quick proce-
dure, requiring approximately 10 min, and has excellent repro-
ducibility with concordance coefﬁcients between intra- and
inter-observer evaluation of 0.98 and 0.97 respectively [12]. Thus
it overcomes traditional liver biopsy shortcomings and is more
accurate than using the Laennec system, which has an inter-
observer agreement of 0.83 [6]. Although it requires the purchase
of specialized software and equipment with a one-off cost of
£6500, it could be argued that given the prognostic and therapeu-
tic implications, quantitative determination of ﬁbrosis (CPA)
should be routinely measured in tertiary liver centers.
Our study included patients with various aetiologies of liver
disease and as mentioned the quantity of ﬁbrosis differs among
different aetiologies [24]. Therefore, CPA might prove an even
more accurate predictor of clinical outcomes in cohorts with sin-
gle liver disease aetiologies with determination of aetiology-spe-
ciﬁc thresholds. This consideration also applies to non-invasiveJournal of Hepatology 201markers (NITs) such as transient elastography [25] and is an area
where further work needs to be done. A comparison of CPA and
NITs is needed with respect to clinical outcomes. In our cohort,
only few patients where categorized in Kumar stage A, Laennec
4a or had thin nodules according to the Nagula system. This
might indeed be an under-representation of lower grades of his-
tological sub-classiﬁcation in this cohort or, more probably,
highlights a somewhat limited reproducibility of such systems
even amongst experienced pathologists in tertiary centers, fur-
ther reinforcing the need of an accurate and reproducible quanti-
tative system of sub-classifying cirrhosis. In our study population
CPA measurement was only feasible in 75% of patients due to
inadequate sample size. This percentage can be improved if TJLB
are preferentially used over PLB, as multiple passes can guarantee
adequate sample size [26]. Conversely, transient elastography is
not feasible in 18% of patients and also in patients with ascites,
therefore in Child-Pugh B and above [27]. Serum NITs are feasible
in >95% of patients.
In conclusion, we have shown that cirrhosis can be accurately
sub-classiﬁed using quantiﬁcation of ﬁbrosis with CPA in liver
biopsy samples P10 mm in length and furthermore that CPA is
the only independent predictor of clinical decompensation
amongst all other histological sub-classiﬁcation systems
described to date. Our new understanding of the natural history,
prognosis and prevention of complications in cirrhosis requires
that accurate tools of sub-classiﬁcation are developed, validated
and used in routine clinical practice and CPA already fulﬁlls the
ﬁrst two essential steps. Finally, future work should also evaluate
a comparison of non-invasive markers with quantitative histolog-
ical parameters against clinical outcomes in patients with
advanced ﬁbrosis, so that the validity and accuracy of all avail-
able tools can be fully assessed.Conﬂict of interest
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